STUDY ON THE SITUATION OF DERMATOPHYTOSIS ON FACIAL CORTICOSTEROID ADDICTIVE DERMATITIS PATIENTS AT CAN THO HOSPITAL OF DERMATO-VENEREOLOGY AND CAN THO UNIVERSITY OF MEDICINE AND PHARMACY HOSPITAL IN 2021-2022

Thi Ngoc Minh Nguyen1,, Thanh Thao Pham1, Van Ba Huynh1
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: Facial corticosteroid addictive dermatitis (FCAD) has recently emerged as a dermatological problem of concern in Viet Nam and other countries. Currently, there are very few studies on dermatophytosis in facial corticosteroid-addictive dermatitis patients. Objective: To determine the prevalence and some factors related to dermatophyte infection in facial corticosteroid-addictive dermatitis. Subjects and methods: A cross-sectional descriptive study on 153 patients (17 males and 136 females) diagnosed with facial corticosteroid addictive dermatitis were tested for dermatophytes and were included in the study. Results: There are 30/153 (19.6%) facial corticosteroid addictive dermatitis patients positive for dermatophytes, in which the proportion of men (41.2%) was 3.439 times higher than that of women (16.9%). Facial corticosteroid addictive dermatitis patients using active ingredients fluocinolone (34.8%) and betamethasone (33.3%) had the highest rate of dermatophytes infections, mainly focusing on using topical corticosteroids to treat skin diseases (40.0%). The prevalence of dermatophytes was predominant in the subjects with dermatitis (28.4%) with unknown lesion limits (51.8%) and severe lesions (44.4%). This difference is statistically significant with p<0.05. Conclusion: The prevalence of dermatophytes in facial corticosteroid-addictive dermatitis patients is quite high and depends on the use of topical corticosteroids to treat skin diseases with common symptoms of pain and burning; lesions of unknown limit and severity.

Article Details

References

1. Huỳnh Văn Bá, Hồ Minh Chánh (2018), “Nghiên cứu tình hình, đặc điểm lâm sàng, kết quả điều trị BN nấm da do bôi corticoid tại Bệnh viện Da liễu thành phố Cần Thơ năm 2017-2018”, Đại học Y Dược Cần Thơ.
2. Phạm Huy Hoàng (2015), “Nghiên cứu đặc điểm lâm sàng, các yếu tố liên quan của nấm da trên bệnh nhân dùng corticoid (tinea incognito) và hiệu quả điều trị bằng uống itraconazol”, Trường Đại học Y Hà Nội, Trường Đại học Y Hà Nội, Hà Nội.
3. Abir Saraswat, Koushik Lahiri, Manas Chatterjee, et al. (2011), “Topical corticosteroid abuse on the face: A prospective, multicenter study of dermatology outpatients”, Indian Journal of Dermatology, Venereology, and Leprology, 77(2), pp.160.
4. Amit Chauhan, Ghanshyam Verma, Gita Ram Tegta, et al. (2019), “An observational study to evaluate the dermatological manifestations of topical corticosteroid abuse on face”, J Med Sci Clin Res, 7, pp.305-310.
5. H Lu (2006), “Facial corticosteroid addictive dermatitis”, Journal Of Clinical DermatologyNanjing-, 35(10), pp.682.
6. Koushik Lahiri, Arijit Coondoo (2016), “Topical steroid damaged/dependent face (TSDF): An entity of cutaneous pharmacodependence”, Indian journal of dermatology, 61(3), pp.265.
7. Roberto Arenas, Gabriela Moreno-Coutiño, Lucio Vera, et al. (2010), “Tinea incognito”, Clinics in dermatology, 28(2), pp.137-139.
8. Soniya Meena, Lalit Kumar Gupta, Ashok Kumar Khare, et al. (2017), “Topical corticosteroids abuse: A clinical study of cutaneous adverse effects”, Indian journal of dermatology, 62(6), pp.675.
9. Tamar Hajar, Yael A Leshem, Jon M Hanifin, et al. (2015), “A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses”, Journal of the American Academy of Dermatology, 72(3), 541-549. e542.
10.Won-Jeong Kim, Tae-Wook Kim, Je-Ho Mun, et al. (2013), “Tinea incognito in Korea and its risk factors: nine-year multicenter survey”, Journal of Korean medical science, 28(1), pp.145-151.
11. Zewdu, A Abdulkerim, MD Nigatu, et al. (2017), “Topical corticosteroid misuse among females attending at dermatology outpatien t department in Ethiopia”, Trichol Cos-metol Open J, 1(1), pp.33-36.